An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
Natasha B. Leighl(Robarts Clinical Trials), Bishal Gyawali(Nagoya University Hospital)
Cited by 167
Related Papers
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
|Oncotarget|2017|29
Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot
|American Society of Clinical Oncology Educational Book|2022|21
Cancer drugs in LMICs: cheap but unaffordable
|Oncotarget|2017|12
(untitled)
|Oncotarget|2017|9